From: Molecular imaging of rheumatoid arthritis: emerging markers, tools, and techniques
Tracer | Target | Developmental phase | Reference |
---|---|---|---|
General tracers | Â | Â | Â |
18 F-fluoro-2-deoxy-D-glucose | Glucose metabolism, inflammation | Clinical use for detection of inflammation and cancer | |
99mTc-diphosphonates | Alterations in bone metabolism, osteoblastic activity | Clinical use for bone scanning | |
11C-choline | Cell membrane synthesis, inflammation | Clinical use for detection of prostate cancer | |
Trial in 10 patients with inflammatory joint disease | |||
67Ga-citrate | Circulating blood plasma proteins and leukocytes, inflammation | Clinical use for detection of inflammation | [14] |
99mTc-polyclonal human immunoglobulin G | Increase in vascular permeability, hyperemia, inflammation | Multiple trials in patients with rheumatic disorders | |
99mTc-/111In-labeled leukocytes | Influx of leukocytes into inflamed tissue | Clinical use for infectious and inflammatory disorders | [40] |
Multiple trials in patients with RA | |||
99mTc-RP128 | Leukocytes (binds to receptors on neutrophils and mononuclear phagocytes) | Trial with 10 patients with RA | [41] |
Radiolabeled biologicals | |||
99mTc-anti-CD4 mAb | T cells | Case study in 1 patient with RA, trial in 6 patients with RA | |
99mTc-anti-CD3 mAb | T cells | Trials in 7 patients with RA, 2 psoriatic arthritis patients, and 38 patients with RA | |
123I-IL-1Ra | Inflammation | Trial in 4 patients with active RA | [49] |
99mTc-anti-TNF-α | Inflammation | Multiple trials with patients with RA | |
Phase 3 study (NCT01590966) | |||
99mTc-/124I-anti-CD20 mAb | B cells | Trials in 6 patients with RA and 20 patients with chronic inflammatory autoimmune disease | |
Specific molecular markers | |||
99mTc-acetylated poly-(1,3)-D-galactoside | Mononuclear phagocyte trafficking (binds CD14 and CD11b) | Trials for tumoral, inflammatory and infectious diseases | [55] |
Preclinical, rabbit antigen-induced arthritis | |||
99mTc-/111In-octreotide | Endothelium activation and macrophage recruitment (binds to somatostatin receptor) | Clinical use for detection of tumors | [56] |
Trial in 14 patients with RA | |||
11C-(R)-PK11195 | Monocytes and macrophages (binds to peripheral benzodiazepine receptors) | Trials in 11 patients with RA, 6 patients with RA, and 29 patients with arthralgia | |
111In-E-selectin-binding peptide | Activated vascular endothelium | Preclinical, rat adjuvant arthritis | [59] |
99mTc-anti-E-selectin Fab/(Fab′)2 fragment | Activated vascular endothelium | Trial in 26 patients with RA | [60] |
NIR-anti-E-selectin Ab | Activated vascular endothelium | Preclinical, CIA, and TNF-α-induced paw edema | [61] |
99mTc-annexin V | Apoptosis (binds to phosphatidylserine) | Multiple trials in cancer patients | [62] |
Preclinical, CIA | |||
Cy5.5-anti-F4/80 | Macrophages | Preclinical, AIA | [63] |
99mTc-anti-IL-6R | Inflammation | Preclinical, murine arthritis model | [64] |
99mTc-folic acid (EC20) | Activated macrophages, folate receptor | Phase 2 study in patients with autoimmune disease (NCT00588393) | |
NIR2-folate | Activated macrophages, folate receptor | Mouse arthritis models | [68] |
18 F-PEG-folate | Activated macrophages, folate receptor | Preclinical, methylated bovine serum albumin-induced arthritis | [69] |
64Cu-/18 F-galacto-arginine-glycine-aspartic acid | Activated macrophages, osteoclasts, endothelial cells | Clinical use, tumor angiogenesis | [70] |
Preclinical, osteopetrosis, and osteoporosis mouse models | |||
NIR-matrix metalloproteinase-specific probe | Sites of matrix degradation and inflammation | Preclinical, CIA, rat OA | [71] |
99mTc-anti-macrophage mannose receptor | Subset of macrophages | Preclinical, CIA | [72] |